Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 136 clinical trials
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. The study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part …

alopecia
solid tumour
targeted therapy
mitomycin
hormone therapy
Georgetown University - Lombardi Comprehensive Cancer Center
 (7.9 away) Contact site
  • 7 views
  • 16 Aug, 2021
  • +27 other locations
Reference Values for Plasma Catechols

Objectives: Plasma levels of catechols have distinct meanings in terms of indicating functions of endogenous catecholamine systems. This Protocol is designed to enable ongoing quality assurance of diagnostic and research assays of catechols and their metabolites and to identify possible influences of demographic and anthropometric factors, dietary constituents, and conditions …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 61 views
  • 06 Aug, 2021
  • 1 location
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

This study is looking to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lyso-thermosensitive liposomal doxorubicin (LTLD) administered in combination with MR-HIFU in children with relapsed/refractory solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma family …

stem cell transplantation
solid tumor
solid tumour
myelosuppression chemotherapy
biological therapy
Children's National Medical Center
 (5.4 away) Contact site
  • 50 views
  • 03 Mar, 2021
  • 1 location
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

Background Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect. Objective Main Study: To study …

anxiety
major depressive disorder
depressive disorder
depressive episode
ketamine
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 1858 views
  • 15 Sep, 2021
  • 1 location
Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta 3-Adrenergic Receptor Agonists

Background Brown adipose tissue (BAT) is a type of fat in the body. It may prevent weight gain, improve insulin sensitivity, and reduce fatty liver. Researchers want to see if BAT helps the body burn energy. Objective To learn more about how BAT works to burn energy. Eligibility Healthy people …

body mass index
insulin
hysterectomy
fasting
vitamins
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 257 views
  • 08 Sep, 2021
  • 1 location
T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation

This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors. In this trial, we will utilize a rapid generation protocol for broad …

parainfluenza
stem cell transplantation
antiviral drugs
prednisone
cmv infection
Childrens National Medical Center
 (5.4 away) Contact site
  • 54 views
  • 25 Jan, 2021
  • 1 location
Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors

Patients with high-risk solid tumors, those that are refractory to standard up front therapy or relapse after completion of therapy, have a very poor prognosis despite attempts to induce remission with salvage regimen. Novel therapies are critical for this patient population with high-risk cancer. The ability of tumors to be …

cancer
lymphoma
conventional therapy
sarcoma
Children's National Medical Center
 (5.4 away) Contact site
  • 0 views
  • 07 Mar, 2021
  • 1 location
Phase I Study of APX005M in Pediatric CNS Tumors

This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed diffuse intrinsic pontine glioma. APX005M can trigger activation of B cells, monocytes, and dendritic cells …

dipg
mri of spine
germ cell tumor
astrocytoma
growth factor
Childrens National Medical Center
 (5.3 away) Contact site
  • 165 views
  • 26 Jan, 2021
  • +10 other locations
Highly Conformal Hypofractionated Focally Dose Escalated Post-Prostatectomy Radiotherapy

Background Sometimes prostate cancer comes back after a person s prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective. It is usually given in short doses almost every day for 6 or 7 weeks. Researchers want to see …

immunological adjuvant
blood test
cancer
prostatectomy
adenocarcinoma
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 3 views
  • 12 Sep, 2021
  • 1 location
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Background The drug IL-15 activates the immune system. The drugs nivolumab and ipilimumab unblock immune cells. The drugs together may allow immune cells to recognize and attack cancer cells, causing tumors to shrink. Objective To test the effects and maximum dose of IL-15, nivolumab, and ipilimumab. Eligibility People ages 18 …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 0 views
  • 12 Sep, 2021
  • 1 location